BiotechTube

DISC-1459 + DISC-1459

Phase 2/3Recruiting
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erythropoietic Protoporphyria

Conditions

Erythropoietic Protoporphyria

Trial Timeline

Aug 31, 2023 → Jun 1, 2028

NCT ID
NCT05883748

About DISC-1459 + DISC-1459

DISC-1459 + DISC-1459 is a phase 2/3 stage product being developed by Disc Medicine for Erythropoietic Protoporphyria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05883748. Target conditions include Erythropoietic Protoporphyria.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT05883748Phase 2/3Recruiting

Competing Products

8 competing products in Erythropoietic Protoporphyria

See all competitors
ProductCompanyStageHype Score
DISC-1459 + DISC-1459 + PlaceboDisc MedicinePhase 2
47
Placebo + DISC-1459Disc MedicinePhase 3
72
AfamelanotideClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide 16mg implantClinuvel PharmaceuticalsPhase 1/2
33
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 2
44
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69

Other Products from Disc Medicine

Placebo + DISC-1459Phase 3
72
DISC-0974 + PlaceboPhase 2
47
DISC-1459 + DISC-1459 + PlaceboPhase 2
47
DISC-3405Phase 2
47
DISC-0974Phase 1/2
36